相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
S. Welch et al.
ANNALS OF ONCOLOGY (2010)
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
Alfredo Carrato Mena et al.
ANTI-CANCER DRUGS (2010)
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Adi F. Gazdar
CANCER AND METASTASIS REVIEWS (2010)
Triple-Negative Breast Cancer Role of Antiangiogenic Agents
Sally Greenberg et al.
CANCER JOURNAL (2010)
Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data
David F. McDermott et al.
CANCER TREATMENT REVIEWS (2010)
Bevacizumab in the treatment of breast cancer
Angelos K. Koutras et al.
CANCER TREATMENT REVIEWS (2010)
Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor
Diego Alvarado et al.
CELL (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
F. Stegmeier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
F. Loupakis et al.
CURRENT CANCER DRUG TARGETS (2010)
Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
A. Ruzzo et al.
CURRENT CANCER DRUG TARGETS (2010)
CETUXIMAB: From Bench to Bedside
B. Vincenzi et al.
CURRENT CANCER DRUG TARGETS (2010)
Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Aude-Helene Capietto et al.
CURRENT DRUG TARGETS (2010)
Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
A. De Luca et al.
CURRENT DRUG TARGETS (2010)
Angiogenesis inhibitors in the management of breast cancer
Verena Bossung et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2010)
Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope
Suresh S. Ramalingam et al.
CURRENT OPINION IN ONCOLOGY (2010)
Rituximab for the Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia
Fredrick Hagemeister
DRUGS (2010)
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
Grzegorz Korpanty et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2010)
HER-dimerization inhibitors: evaluating pertuzumab in women's cancers
Katrin Kristjansdottir et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Pertuzumab for the treatment of ovarian cancer
Simon P. Langdon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
HER2 as a target for breast cancer therapy
Elda Tagliabue et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
Fabricio F. T. Barros et al.
HISTOPATHOLOGY (2010)
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles
Saskia A. G. M. Cillessen et al.
JOURNAL OF PATHOLOGY (2010)
Targeted Therapies: The Rare Cancer Paradigm
Marco A. Pierotti et al.
MOLECULAR ONCOLOGY (2010)
The future of CD20 monoclonal antibody therapy in B-cell malignancies
Myron S. Czuczman et al.
LEUKEMIA & LYMPHOMA (2010)
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
Xin An et al.
LEUKEMIA RESEARCH (2010)
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Francisco J. Esteva et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Fumin Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Stephen A. Beers et al.
SEMINARS IN HEMATOLOGY (2010)
Molecular basis and management of gastrointestinal stromal tumors
Ulas D. Bayraktar et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Tyrosine Kinase Inhibitors: The First Decade
Meetu Agrawal et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2010)
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Natalia Jura et al.
CELL (2009)
Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop
Nicole E. Willmarth et al.
CELLULAR SIGNALLING (2009)
Ligand-induced ErbB receptor dimerization
Mark A. Lemmon
EXPERIMENTAL CELL RESEARCH (2009)
Functional selectivity of EGF family peptide growth factors: Implications for cancer
Kristy J. Wilson et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Structural basis for EGFR ligand sequestration by Argos
Daryl E. Klein et al.
NATURE (2008)
Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells
Jennifer L. Gilmore et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Inter-conversion of neuregulin2 full and partial agonists for ErbB4
Kristy J. Wilson et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis
David J. Riese et al.
BIOESSAYS (2007)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2β and agonist-independent coupling with downstream signalling events
Jennifer L. Gilmore et al.
BIOCHEMICAL JOURNAL (2006)
Electrostatic interactions of peptides flanking the tyrosine kinase domain in the epidermal growth factor receptor provides a model for intracellular dimerization and autophosphorylation
S Aifa et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2006)
Phe45 of NRG2β is critical for the affinity of NRG2β for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2β
SS Hobbs et al.
GROWTH FACTORS (2005)
Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase
SS Hobbs et al.
ONCOGENE (2004)
Argos inhibits epidermal growth factor receptor signalling by ligand sequestration
DE Klein et al.
NATURE (2004)
A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains
M Landau et al.
STRUCTURE (2004)
Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation
SS Hobbs et al.
ONCOGENE (2002)
分享论文
